NL-OMON50873已完成不适用
A RANDOMIZED, DOUBLE-BLINDED, DOUBLE-DUMMY, PLACEBO-CONTROLLED THOROUGH QTC STUDY WITH SINGLE ORAL DOSES OF CEDAZURIDINE IN HEALTHY SUBJECTS - Thorough QT Assessment of Cedazuridine in Healthy Subjects
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Sex : male or female; females of nonchildbearing potential, or
- •postmenopausal.
- •2. Age : 18 to 55 years, inclusive, at screening.
- •3. Body mass index (BMI) : 18.0 to 32.0 kg/m2, inclusive.
- •4. Weight : >=50 kg, inclusive.
- •5. Status : healthy subjects.
排除标准
- •1. Employee of PRA or the Sponsor.
- •2. History of relevant drug and/or food allergies.
- •3. History of alcohol abuse or drug addiction (including soft drugs like
- •cannabis products).
- •4. History or presence of atrioventricular block (any degree) or sick sinus
研究者
相似试验
未知
不适用
A RANDOMIZED, DOUBLED-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED MULTI-CENTRE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FLUTICASONE FUROATE INHALATION POWDER AND FLUTICASONE PROPIONATE INHAATION POWDER IN THE TREATMENT OF ASTHMA IN ADULTS AND ADOLESCENTS NOT CURRENTLY TREATED WITH INHALED CORTICOSTEROIDSPER-076-11GLAXOSMITHKLINE PERU S.A.,119
未知
不适用
A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, MULTICENTER STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE EFFICACY AFTER TWELVE WEEKS OF TREATMENT, COMPARED PLACEBO AND ETANERCEPT AND TO ASSESS THE SAFETY, TOLERABILITY AND LONG-TERM EFFICACY UP TO ONE YEAR IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE-TYPE PSORIASISPER-054-11OVARTIS BIOSCIENSES PERU S.A.,
进行中（未招募）
1 期
A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (TURANDOT) - TURANDOTCrohn’s Disease (CD) and Ulcerative Colitis (UC)MedDRA version: 14.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2012-002030-37-BEPfizer Inc.357
进行中（未招募）
不适用
A PHASE II STUDY ASSESSING RANOLAZINE IN ATRIAL FIBRILLATION FOLLWING AN ELECTRICAL CARDIOVERSIOON-PERMANENT ATRIAL FIBRILLATIONMedDRA version: 14.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2011-002789-18-DEMenarini Ricerche S.p.A240
进行中（未招募）
1 期
A PHASE II STUDY ASSESSING RANOLAZINE IN ATRIAL FIBRILLATION FOLLOWING AN ELECTRICAL CARDIOVERSIOON-PERMANENT ATRIAL FIBRILLATIONMedDRA version: 14.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2011-002789-18-ESMENARINI RICERCHE S.P.A241